Top

memo - Magazine of European Medical Oncology

Published in:

01-12-2019 | Geriatric Oncology | editorial

Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?

Author: Rupert Bartsch

Published in: memo - Magazine of European Medical Oncology | Issue 4/2019

Excerpt

Fundamental progress has been achieved in the treatment of solid cancers over the last two decades and patients’ long-term outcome has improved accordingly. With monoclonal antibodies, small-molecule tyrosine kinase inhibitors and more recently, immune checkpoint modulators, a plethora of highly active novel drugs has become available. But are truly all patients benefitting from these successes? In an elderly population of breast cancer patients, the HER2-positive subtype was still associated with the worst prognosis as shown in a recent publication [1] despite the excellent survival results achieved within clinical trials [2]. …

Bergen ES, Tichy C, Berghoff AS, et al. Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Res Treat. 2016;157(1):91–9.CrossRef

Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.CrossRef

Zeber JE, Copeland LA, Hosek BJ, Karnad AB, Lawrence VA, Sanchez-Reilly SE. Cancer rates, medical comorbidities, and treatment modalities in the oldest patients. Crit Rev Oncol Hematol. 2008;67(3):237–342.CrossRef

Balic M, Hilbe W, Gusel S, et al. Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria. A cross-sectional multicenter observational study. memo. 2019;12(4). https://doi.org/10.1007/s12254-019-00542-7.CrossRef

Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–92.CrossRef

Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.CrossRef

Title: Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?
Author: Rupert Bartsch
Publication date: 01-12-2019
Publisher: Springer Vienna
Keywords: Geriatric Oncology
Geriatric Oncology
Published in: memo - Magazine of European Medical Oncology / Issue 4/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00535-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

Targeted therapy in lung cancer—ASCO 2019 update

First-line treatment of metastatic renal cell carcinoma: current standard of care

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

An update from the 2019 ASCO Annual Meeting

ASCO 2019: highlights in HER2-positive metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer